Spinal muscular atrophy (SMA) type 1 is a severe genetic neuromuscular disease that affects babies in the first months of life and causes progressive muscle weakness, especially in the muscles needed for breathing, swallowing, and movement. It is the most common and typically the most serious form of SMA, accounting for around 60% of SMA cases.

What SMA Type 1 Is

  • SMA type 1 (also called Werdnig‑Hoffmann disease or infantile-onset SMA) is caused by a mutation in the SMN1 gene, which leads to a lack of SMN protein needed for motor neuron survival.
  • The loss of these motor neurons in the spinal cord and brainstem leads to progressive muscle weakness and atrophy, particularly in the trunk, neck, and limb muscles.

When It Starts and Key Symptoms

  • Symptoms usually appear between birth and 6 months of age; infants often never gain the ability to sit independently without support.
  • Common signs include severe low muscle tone (floppiness), poor head control, weak cry, difficulty feeding or sucking, trouble swallowing, and breathing problems due to weak chest muscles.

How Serious It Is and Outlook

  • Historically, before modern treatments, SMA type 1 was often life‑limiting in early childhood because of breathing and swallowing complications.
  • In recent years, disease‑modifying and gene‑replacement therapies have significantly improved survival and motor outcomes, so many children now live longer and reach more developmental milestones than previously expected.

Diagnosis and Cause

  • Diagnosis usually starts with a physical exam and review of symptoms, then is confirmed by a blood test showing an SMN1 gene mutation.
  • SMA type 1 is inherited in an autosomal recessive manner, meaning both parents typically carry one faulty copy of the SMN1 gene, even though they usually have no symptoms.

Treatment and Care (High Level)

  • Current medical care may include medications that boost or replace SMN protein (for example, antisense or gene therapies), along with respiratory, nutritional, physical, and occupational therapy support.
  • Management is usually done by a multidisciplinary team (neurology, pulmonology, nutrition, rehabilitation) to support breathing, feeding, mobility, and overall quality of life.

Note: For any real‑world situation involving SMA type 1, families should work closely with a pediatric neurologist or neuromuscular specialist, as individual prognosis and treatment options can vary greatly with today’s therapies.